Trials / Active Not Recruiting
Active Not RecruitingNCT05844150
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of PM8002 in Combination With Etoposide and Platinum in First-line Treatment of Extensive-Stage Small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Biotheus Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study to evaluate the efficacy and safety of PM8002 in combination with etoposide and platinum in first-line treatment of extensive-stage small cell lung cancer
Detailed description
The study is divided into two parts. The first part is single-arm study, 50 participants were enrolled as of 21 Nov 2023，and recruitment was completed. The second part is randomized, double-blind study, active controlled design , which will be integrated to another global III study （NCT06712355）.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PM8002 | IV infusion |
| DRUG | Platinum | IV infusion |
| DRUG | Etoposide | IV infusion |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2024-05-10
- Completion
- 2025-12-01
- First posted
- 2023-05-06
- Last updated
- 2025-03-12
Locations
17 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05844150. Inclusion in this directory is not an endorsement.